Vol. 2 No. 3 (2022)
Reimbursement Reviews

Alpelisib (Piqray)

Published March 17, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses alpelisib (Piqray), in 50 mg, 150 mg, and 200 mg oral tablets.
  • Indication: Alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.